论文部分内容阅读
目的:研究胃癌患者外周血清中可溶性CD44v6(sCD44v6)含量/CD44v6蛋白表达,及其与临床病理参数之间的关系。方法:应用定量ELISA方法检测胃癌患者(术前和术后)及健康对照组血清中sCD44v6含量,并以(S-P)免疫组化法测定相应组织中CD44v6蛋白的表达。结果:70例胃癌患者血清中sCD44v6含量(2.15±0.78 ng/ml)明显高于16例正常对照组(1.18±0.43 ng/ml),14树根治性手术后血清中sCD44v6含量(1.21±0.39 ng/ml)比术前(2.67±0.83 ng/ml)明显下降(P<0.01),而6例非根治性手术后(3.29±0.41ng/ml)比术前(3.61+0.49 ng/ml)下降不明显(P>0.05)。而胃癌组织中CD44v6蛋白表达在肠型和弥漫型中有显著差异,不同的浸润深度、有无淋巴结及远处转移也有显著差异。结论:胃癌患者外周血清中sCD44v6含量及组织中CD44v6蛋白表达的变化与转移、临床分期、病理分期有关,sCD44v6含量升高可作为胃癌患者淋巴结转移(尤其是早期转移)的监测指标。
Objective: To investigate the expression of soluble CD44v6 (sCD44v6) / CD44v6 protein in peripheral blood of gastric cancer patients and its relationship with clinicopathological parameters. Methods: The serum sCD44v6 levels in gastric cancer patients (preoperative and postoperative) and healthy controls were detected by quantitative ELISA. The expression of CD44v6 protein in the corresponding tissues was detected by (S-P) immunohistochemistry. Results: Serum levels of sCD44v6 in 70 patients with gastric cancer (2.15 ± 0.78 ng / ml) were significantly higher than those in 16 healthy controls (1.18 ± 0.43 ng / ml) and sCD44v6 (1.21 ± 0.39 ng / ml) was significantly lower than preoperative (2.67 ± 0.83 ng / ml) (P <0.01), while 6 cases after non-radical operation (3.29 ± 0.41 ng / ml) Not obvious (P> 0.05). However, the expression of CD44v6 protein in gastric carcinoma was significantly different between intestinal type and diffuse type. There were also significant differences in the depth of invasion, lymph node metastasis and distant metastasis. Conclusion: The changes of sCD44v6 in peripheral blood serum and the expression of CD44v6 protein in gastric cancer patients are related with the metastasis, clinical stage and pathological stage. The increased sCD44v6 may be used as the monitoring indicator of lymph node metastasis (especially early metastasis) in gastric cancer patients.